Payment overview · 2025
General Payments
$3,114.33
195 reported records · 31 companies
Healthcare provider profile · identity verified
Robert P Suer, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MUNCIE, IN · NPI 1902957400
Verified facts
What the public records show
CMS Open Payments records show Robert P Suer, M.D. received $3,114.33 in general payments during 2025 across 195 reported records.
AstraZeneca Pharmaceuticals LP accounted for 15.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 56 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Arexvy, Creon, Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Paxlovid, Rybelsus, Shingrix, Trelegy Ellipta, Trintellix, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexium by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 540 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 678 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 540 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 232 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 678 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xifaxan by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $486.99 | 15.6% | 21 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $450.63 | 14.5% | 25 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $333.95 | 10.7% | 34 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $227.49 | 7.3% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $191.89 | 6.2% | 17 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $182.85 | 5.9% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $154.43 | 5.0% | 12 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $150.71 | 4.8% | 9 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $148.38 | 4.8% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $90.53 | 2.9% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $78.38 | 2.5% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $75.15 | 2.4% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $65.50 | 2.1% | 4 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $50.23 | 1.6% | 2 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $48.97 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.31 | 1.6% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.24 | 1.4% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$35.44 | 1.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $34.13 | 1.1% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.38 | 0.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $24.29 | 0.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.29 | 0.8% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.09 | 0.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.73 | 0.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.27 | 0.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.39 | 0.5% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.83 | 0.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.67 | 0.5% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $14.57 | 0.5% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $13.99 | 0.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.63 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,114.33 | 195 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $380.71 | 15 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $307.81 | 16 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $188.46 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $180.27 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $168.10 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $167.88 | 13 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $157.61 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $157.61 | 12 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $150.71 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $149.69 | 14 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $134.92 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $134.10 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $131.18 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $113.66 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $107.10 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $106.87 | 9 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $96.07 | 7 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $78.38 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $75.15 | 4 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $58.64 | 7 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $53.06 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $53.06 | 5 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $50.23 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $48.97 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $48.97 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $42.24 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $39.03 | 2 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $35.44 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $34.13 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $34.13 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $34.05 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $33.03 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.24 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $31.28 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $30.65 | 3 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $29.32 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $25.24 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $24.38 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.29 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $24.29 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $23.25 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.53 | 6 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.14 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $2.47 | 3 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $0.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 33 | exact normalized | Medicare Part D |
| AREXVY arexvy |
2025 | Arexvy | 2024 | 116 | exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 678 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 173 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 540 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 66 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 139 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 232 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 32 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 83 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 125 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
66 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
102 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
173 | 45 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
540 | 69 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
678 | 77 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
116 | 116 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
83 | 77 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
125 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
540 | 69 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
139 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | 16 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
232 | 48 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
150 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
33 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
678 | 77 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
32 | 31 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1822 | 294 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1197 | 169 |
| Amlodipine Besylate | Amlodipine Besylate | 888 | 159 |
| Potassium Chloride | Potassium Chloride | 721 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 711 | 113 |
| Eliquis | Apixaban | 678 | 77 |
| Lisinopril | Lisinopril | 671 | 123 |
| Metformin Hcl | Metformin Hcl | 632 | 107 |
| Omeprazole | Omeprazole | 622 | 98 |
| Furosemide | Furosemide | 567 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 554 | 96 |
| Gabapentin | Gabapentin | 549 | 91 |
| Jardiance | Empagliflozin | 540 | 69 |
| Torsemide | Torsemide | 492 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 488 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 454 | 76 |
| Losartan Potassium | Losartan Potassium | 430 | 95 |
| Buspirone Hcl | Buspirone Hcl | 429 | 34 |
| Memantine Hcl | Memantine Hcl | 408 | 51 |
| Donepezil Hcl | Donepezil Hcl | 365 | 49 |
| Quetiapine Fumarate | Quetiapine Fumarate | 364 | 16 |
| Trazodone Hcl | Trazodone Hcl | 347 | 61 |
| Famotidine | Famotidine | 328 | 26 |
| Tramadol Hcl | Tramadol Hcl | 312 | 84 |
| Clopidogrel | Clopidogrel Bisulfate | 306 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 304 | 58 |
| Sertraline Hcl | Sertraline Hcl | 298 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 287 | 47 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 283 | suppressed |
| Carvedilol | Carvedilol | 280 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 274 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 273 | 77 |
| Allopurinol | Allopurinol | 269 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 253 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 246 | 52 |
| Citalopram Hbr | Citalopram Hydrobromide | 245 | 36 |
| Montelukast Sodium | Montelukast Sodium | 240 | 37 |
| Ozempic | Semaglutide | 232 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 222 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 203 | 19 |
| Azithromycin | Azithromycin | 197 | 116 |
| Fluoxetine Hcl | Fluoxetine Hcl | 194 | 29 |
| Simvastatin | Simvastatin | 180 | 42 |
| Farxiga | Dapagliflozin Propanediol | 173 | 45 |
| Alprazolam | Alprazolam | 170 | 38 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 164 | 11 |
| Alendronate Sodium | Alendronate Sodium | 159 | 21 |
| Prednisone | Prednisone | 154 | 53 |
| Mirtazapine | Mirtazapine | 152 | 21 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 150 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 146 | suppressed |
| Levetiracetam | Levetiracetam | 142 | 16 |
| Mounjaro | Tirzepatide | 139 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 136 | 35 |
| Paroxetine Hcl | Paroxetine Hcl | 132 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 47 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 125 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 122 | 81 |
| Dapagliflozin | Dapagliflozin Propanediol | 122 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 121 | 26 |
| Baclofen | Baclofen | 117 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 116 | 116 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 115 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 53 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 111 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 110 | 32 |
| Fenofibrate | Fenofibrate Nanocrystallized | 110 | suppressed |
| Gemtesa | Vibegron | 104 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 103 | 27 |
| Risperidone | Risperidone | 103 | suppressed |
| Ezetimibe | Ezetimibe | 102 | 18 |
| Synthroid | Levothyroxine Sodium | 102 | 26 |
| Atenolol | Atenolol | 101 | 27 |
| Benztropine Mesylate | Benztropine Mesylate | 101 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 101 | suppressed |
| Spironolactone | Spironolactone | 97 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 95 | 29 |
| Aripiprazole | Aripiprazole | 93 | suppressed |
| Clonazepam | Clonazepam | 92 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 91 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 90 | 56 |
| Meloxicam | Meloxicam | 90 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 90 | 14 |
| Finasteride | Finasteride | 88 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 86 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 86 | 15 |
| Celecoxib | Celecoxib | 83 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 83 | 77 |
| Solifenacin Succinate | Solifenacin Succinate | 83 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 83 | 29 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 78 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 76 | 58 |
| Diazepam | Diazepam | 71 | suppressed |
| Estradiol | Estradiol | 69 | 25 |
| Bupropion Xl | Bupropion Hcl | 68 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 68 | 18 |
| Linzess | Linaclotide | 66 | 12 |
| Nystatin | Nystatin | 66 | 22 |
| Methotrexate | Methotrexate Sodium | 64 | suppressed |
| Insulin Lispro | Insulin Lispro | 61 | 13 |
| Pregabalin | Pregabalin | 61 | 13 |
| Digoxin | Digoxin | 59 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 59 | suppressed |
| Paliperidone Er | Paliperidone | 58 | suppressed |
| Metolazone | Metolazone | 56 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 55 | 17 |
| Fluconazole | Fluconazole | 55 | 24 |
| Colchicine | Colchicine | 53 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 52 | suppressed |
| Methylprednisolone | Methylprednisolone | 51 | 47 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 50 | 36 |
| Sumatriptan Succinate | Sumatriptan Succinate | 50 | suppressed |
| Glimepiride | Glimepiride | 46 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 45 | suppressed |
| Amoxicillin | Amoxicillin | 44 | 25 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 44 | suppressed |
| Entacapone | Entacapone | 44 | suppressed |
| Trulicity | Dulaglutide | 44 | 16 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 43 | 43 |
| Entresto | Sacubitril/Valsartan | 43 | suppressed |
| Glipizide | Glipizide | 43 | suppressed |
| Naproxen | Naproxen | 43 | 12 |
| Sotalol | Sotalol Hcl | 42 | suppressed |
| Lorazepam | Lorazepam | 39 | 12 |
| Metformin Hcl Er | Metformin Hcl | 34 | 12 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 33 | 33 |
| Flecainide Acetate | Flecainide Acetate | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 17 |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 31 |
| Raloxifene Hcl | Raloxifene Hcl | 32 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 31 | 11 |
| Lovastatin | Lovastatin | 31 | suppressed |
| Nystop | Nystatin | 31 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Humalog | Insulin Lispro | 29 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 29 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Teriflunomide | Teriflunomide | 27 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 27 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | 21 |
| Clonidine Hcl | Clonidine Hcl | 26 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Nateglinide | Nateglinide | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 17 |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Fentanyl | Fentanyl | 25 | suppressed |
| Loperamide | Loperamide Hcl | 25 | 16 |
| Sevelamer Carbonate | Sevelamer Carbonate | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 17 |
| Nitroglycerin | Nitroglycerin | 24 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | 11 |
| Sulfasalazine | Sulfasalazine | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Novolog | Insulin Aspart | 22 | suppressed |
| Repatha Syringe | Evolocumab | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 20 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Roflumilast | Roflumilast | 19 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Indapamide | Indapamide | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 11 |
| Cinacalcet Hcl | Cinacalcet Hcl | 15 | suppressed |
| Eplerenone | Eplerenone | 15 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Klonopin | Clonazepam | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Prozac | Fluoxetine Hcl | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Trimethoprim | Trimethoprim | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,114.33 · 195 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, INTELLIS ADAPTIVESTIM, JARDIANCE, KISUNLA, Kerecis GraftGuide, Kerecis SurgiClose, LEQVIO, LINZESS, Leqembi, MOUNJARO, NEXLETOL, NUPLAZID, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SAPIEN 3 Ultra RESILIA, SHINGRIX, Symbravo, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VIBERZI, VOQUEZNA, VRAYLAR, VYEPTI, VYNDAQEL, Veozah, WATCHMAN FLX, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 26 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error